^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN2

    i
    Other names: GEN2, Reximmune-C2, HSV- Thymidine Kinase-m2 and hGM-CSF Genes
    Associations

    News

    Trials
    Company:
    GenVivo
    Drug class:
    Thymidine kinase stimulant
    Related drugs:
    Associations

    News

    Trials
    25d
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Terminated, GenVivo, Inc. | Trial completion date: Mar 2028 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Mar 2026; Sponsor strategic business decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    GEN2 • Valcyte (valganciclovir)
    4ms
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=124 --> 37
    Enrollment closed • Enrollment change
    |
    GEN2 • Valcyte (valganciclovir)
    over1year
    Phase 1 Study of GEN2 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=124, Recruiting, GenVivo, Inc. | N=91 --> 124
    Enrollment change • Metastases
    |
    GEN2 • Valcyte (valganciclovir)
    over1year
    GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
    P1, N=61, Completed, GenVivo, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    GEN2
    almost2years
    Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=91, Recruiting, GenVivo, Inc.
    New P1 trial • Metastases
    |
    GEN2 • Valcyte (valganciclovir)
    almost2years
    GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, GenVivo, Inc. | Recruiting --> Active, not recruiting | N=122 --> 61 | Trial primary completion date: Dec 2023 --> Jun 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    GEN2
    almost3years
    GEN2 Directed Cancer Immunotherapy Trial (clinicaltrials.gov)
    P1, N=122, Recruiting, GenVivo, Inc. | Trial completion date: Mar 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    GEN2